Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free CURX Stock Alerts

Curanex Pharmaceuticals (CURX) Competitors

Curanex Pharmaceuticals logo
$4.49 +0.18 (+4.06%)
Closing price 09/11/2026 03:57 PM Eastern
Extended Trading
$4.45 -0.04 (-0.78%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CURX vs. OPTH, BGM, TXMD, PLRZ, and TVRD

Should you buy Curanex Pharmaceuticals stock or one of its competitors? Curanex Pharmaceuticals's main competitors and comparable companies include Optimi Health (OPTH), BGM Group (BGM), TherapeuticsMD (TXMD), Polyrizon (PLRZ), and Tvardi Therapeutics (TVRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Curanex Pharmaceuticals compare to Optimi Health?

Curanex Pharmaceuticals (NASDAQ:CURX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Optimi Health had 8 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 10 mentions for Optimi Health and 2 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat Optimi Health's score of 0.35 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Curanex Pharmaceuticals Positive
Optimi Health Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Optimi Health
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Optimi Health's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A -82.07% -79.65%
Optimi Health N/A N/A N/A

Optimi Health has higher revenue and earnings than Curanex Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/A-$4.22M-$7.80N/A
Optimi Health$290K87.33-$1.12M-$0.76N/A

Summary

Optimi Health beats Curanex Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to BGM Group?

BGM Group (NASDAQ:BGM) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Curanex Pharmaceuticals has lower revenue, but higher earnings than BGM Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$37.92M0.67-$19.94MN/AN/A
Curanex PharmaceuticalsN/AN/A-$4.22M-$7.80N/A

BGM Group's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Curanex Pharmaceuticals N/A -82.07%-79.65%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, BGM Group and BGM Group both had 2 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat BGM Group's score of 0.67 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
BGM Group Positive
Curanex Pharmaceuticals Positive

Summary

BGM Group beats Curanex Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Curanex Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TherapeuticsMD-6.64% -1.09% -0.78%
Curanex Pharmaceuticals N/A -82.07%-79.65%

TherapeuticsMD has higher revenue and earnings than Curanex Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$3.02M8.28-$570K$0.02108.00
Curanex PharmaceuticalsN/AN/A-$4.22M-$7.80N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TherapeuticsMD
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Curanex Pharmaceuticals had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat Curanex Pharmaceuticals' score of 1.44 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company Overall Sentiment
TherapeuticsMD Very Positive
Curanex Pharmaceuticals Positive

30.7% of TherapeuticsMD shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

TherapeuticsMD beats Curanex Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Polyrizon?

Curanex Pharmaceuticals (NASDAQ:CURX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/A-$4.22M-$7.80N/A
PolyrizonN/AN/A-$3.34MN/AN/A

Polyrizon's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A -82.07% -79.65%
Polyrizon N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Polyrizon
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Curanex Pharmaceuticals and Curanex Pharmaceuticals both had 2 articles in the media. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat Polyrizon's score of 0.94 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Curanex Pharmaceuticals Positive
Polyrizon Positive

Summary

Polyrizon beats Curanex Pharmaceuticals on 3 of the 4 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tvardi Therapeutics$7.14M3.49-$18.21M-$2.79N/A
Curanex PharmaceuticalsN/AN/A-$4.22M-$7.80N/A

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 2 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat Tvardi Therapeutics' score of 0.97 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Tvardi Therapeutics Positive
Curanex Pharmaceuticals Positive

44.7% of Tvardi Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tvardi Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 862.57%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tvardi Therapeutics is more favorable than Curanex Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tvardi Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Curanex Pharmaceuticals' return on equity of -82.07% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tvardi TherapeuticsN/A -145.40% -91.11%
Curanex Pharmaceuticals N/A -82.07%-79.65%

Summary

Tvardi Therapeutics beats Curanex Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CURX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CURX vs. The Competition

Export
MetricCuranex PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$7.14M$12.41B$7.16B$12.85B
Dividend YieldN/A2.64%2.57%11.71%
P/E Ratio-0.57799.75274.9425.33
Price / SalesN/A756.96633.8090.72
Price / CashN/A14.8628.4234.96
Price / Book0.5710.3910.336.21
Net Income-$4.22M$2.85B$3.50B$358.54M
7 Day Performance-11.19%-3.61%-3.32%-2.35%
1 Month Performance2.21%0.72%-0.53%-3.23%
1 Year Performance-97.39%3.61%23.51%8.79%

Curanex Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CURX
Curanex Pharmaceuticals
1.2021 of 5 stars		$4.49
+4.1%		N/A-97.4%$7.14MN/AN/AN/A
OPTH
Optimi Health
1.2014 of 5 stars		$4.81
+1.3%		N/AN/A$27.54M$175.67KN/AN/A
BGM
BGM Group
0.9549 of 5 stars		$0.28
-1.0%		N/A-96.4%$26.83M$37.92MN/A298
TXMD
TherapeuticsMD
1.269 of 5 stars		$2.21
-2.2%		N/A+94.6%$25.57M$3.02M110.50420
PLRZ
Polyrizon
0.9384 of 5 stars		$12.22
-2.4%		N/A+53.2%$25.47MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 9/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel